LOX-1在动脉粥样硬化与心肌缺血中的生物学、遗传学及调控
本文综述凝集素样氧化低密度脂蛋白受体-1(LOX-1)作为ox-LDL的清道夫受体,参与动脉壁细胞摄取ox-LDL,证据提示其在动脉粥样硬化从起始到斑块不稳定的多个环节中起作用。LOX-1基因多态性可能调节动脉粥样硬化性心血管事件风险,其作为治疗靶点受到关注,本文还总结了天然化合物及小分子和生物制剂对LOX-1的调控。
要点
- LOX-1是ox-LDL的清道夫受体,参与动脉壁细胞对ox-LDL的摄取。
- 证据提示LOX-1参与动脉粥样硬化从起始到斑块不稳定的多个步骤。
- LOX-1基因多态性可能调节动脉粥样硬化性心血管事件风险。
核心结论
- LOX-1在动脉粥样硬化发生及心肌缺血中起重要作用,并作为潜在治疗靶点受到关注。
研究设计与样本
- 综述,讨论LOX-1的发现与遗传学、其在动脉粥样硬化及心肌缺血中的证据以及LOX-1调控。
主要发现
- LOX-1是ox-LDL的清道夫受体之一,参与动脉壁细胞摄取ox-LDL。
- 越来越多证据提示LOX-1参与动脉粥样硬化从起始到斑块不稳定的多个步骤。
- LOX-1基因结构研究发现了可能调节动脉粥样硬化性心血管事件风险的多种基因多态性。
- 天然化合物可调控LOX-1,并有研究致力于开发具有治疗用途的小分子和生物制剂。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one of the scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a crucial role in the uptake of ox-LDL by cells in the arterial wall. Mounting evidence suggests a role for LOX-1 in various steps of the atherosclerotic process, from initiation to plaque destabilization. Studies of the genetic structure of LOX-1 have also uncovered various genetic polymorphisms that could modulate the risk of atherosclerotic cardiovascular events. As evidence supporting the vital role of LOX-1 in atherogenesis keeps accumulating, there is growing interest in LOX-1 as a potential therapeutic target. This review discusses the discovery and genetics of LOX-1; describes existing evidence supporting the role of LOX-1 in atherogenesis and its major complication, myocardial ischemia; and summarizes LOX-1 modulation by some naturally occurring compounds and efforts toward development of small molecules and biologics that could be of therapeutic use.
引用
- Pothineni NVK, Karathanasis SK, Ding Z, et al. LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation. J Am Coll Cardiol. 2017. PMID: 28571642. doi:10.1016/j.jacc.2017.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。